Statin therapy and the acute inflammatory response after coronary artery bypass grafting

2001 ◽  
Vol 88 (4) ◽  
pp. 431-433 ◽  
Author(s):  
David J Brull ◽  
Julie Sanders ◽  
Ann Rumley ◽  
Gordon D.O Lowe ◽  
Steve E Humphries ◽  
...  
Keyword(s):  
Coronary Artery ◽  
Coronary Artery Bypass Grafting ◽  
Inflammatory Response ◽  
Statin Therapy ◽  
Coronary Artery Bypass ◽  
Artery Bypass ◽  
Acute Inflammatory Response ◽  
Bypass Grafting ◽  
Artery Bypass Grafting

Statin therapy is associated with reduced total and cardiovascular mortality after coronary artery bypass grafting surgery

2008 ◽  
Vol 19 (8) ◽  
pp. 619-625 ◽  
Author(s):  
Athanasios Papathanasiou ◽  
Ioannis K. Toumpoulis ◽  
Haralampos J. Milionis ◽  
Kallirroi Kalantzi ◽  
Christos S. Katsouras ◽  
...  
Keyword(s):  
Coronary Artery ◽  
Coronary Artery Bypass Grafting ◽  
Statin Therapy ◽  
Coronary Artery Bypass ◽  
Cardiovascular Mortality ◽  
Artery Bypass ◽  
Bypass Grafting ◽  
Artery Bypass Grafting

scholarly journals Perioperative Statin Therapy for Patients Undergoing Coronary Artery Bypass Grafting

2016 ◽  
Vol 101 (2) ◽  
pp. 818-825 ◽  
Author(s):  
Amr F. Barakat ◽  
Marwan Saad ◽  
Ahmed Abuzaid ◽  
Amgad Mentias ◽  
Ahmed Mahmoud ◽  
...  
Keyword(s):  
Coronary Artery ◽  
Coronary Artery Bypass Grafting ◽  
Statin Therapy ◽  
Coronary Artery Bypass ◽  
Artery Bypass ◽  
Bypass Grafting ◽  
Artery Bypass Grafting

scholarly journals Inflammatory Response in Patients under Coronary Artery Bypass Grafting Surgery and Clinical Implications: A Review of the Relevance of Dexmedetomidine Use

2014 ◽  
Vol 2014 ◽  
pp. 1-28 ◽  
Author(s):  
Neusa Maria Heinzmann Bulow ◽  
Elisângela Colpo ◽  
Marta Frescura Duarte ◽  
Eduardo Francisco Mafassioly Correa ◽  
Rochelle Silveira Schlosser ◽  
...  
Keyword(s):  
Cardiopulmonary Bypass ◽  
Coronary Artery ◽  
Coronary Artery Bypass Grafting ◽  
Inflammatory Response ◽  
Coronary Artery Bypass ◽  
Ischemia Reperfusion ◽  
Artery Bypass ◽  
Bypass Grafting ◽  
Artery Bypass Grafting ◽  
Anti Inflammatory

Despite the fact that coronary artery bypass grafting surgery (CABG) with cardiopulmonary bypass (CPB) prolongs life and reduces symptoms in patients with severe coronary artery diseases, these benefits are accompanied by increased risks. Morbidity associated with cardiopulmonary bypass can be attributed to the generalized inflammatory response induced by blood-xenosurfaces interactions during extracorporeal circulation and the ischemia/reperfusion implications, including exacerbated inflammatory response resembling the systemic inflammatory response syndrome (SIRS). The use of specific anesthetic agents with anti-inflammatory activity can modulate the deleterious inflammatory response. Consequently, anti-inflammatory anesthetics may accelerate postoperative recovery and better outcomes than classical anesthetics. It is known that the stress response to surgery can be attenuated by sympatholytic effects caused by activation of central (α-)2-adrenergic receptor, leading to reductions in blood pressure and heart rate, and more recently, that they can have anti-inflammatory properties. This paper discusses the clinical significance of the dexmedetomidine use, a selective (α-)2-adrenergic agonist, as a coadjuvant in general anesthesia. Actually, dexmedetomidine use is not in anesthetic routine, but this drug can be considered a particularly promising agent in perioperative multiple organ protection.

Pre-Operative Atorvastatin Therapy to Decrease the Systemic Inflammatory Response after Coronary Artery Bypass Grafting

2008 ◽  
Vol 36 (6) ◽  
pp. 1248-1254 ◽  
Author(s):  
Y Dereli ◽  
E Ege ◽  
S Kurban ◽  
C Narin ◽  
A Sarigül ◽  
...  
Keyword(s):  
Coronary Artery ◽  
Coronary Artery Bypass Grafting ◽  
Inflammatory Response ◽  
Coronary Artery Bypass ◽  
Ldl Cholesterol ◽  
Artery Bypass ◽  
Systemic Inflammatory Response ◽  
Bypass Grafting ◽  
Artery Bypass Grafting ◽  
Group I

The effect of pre-operative atorvastatin on systemic inflammatory response syndrome (SIRS), often seen after coronary artery bypass grafting (CABG) was evaluated in 40 patients undergoing elective CABG. Patients were divided into two groups: group I (pre-operative LDL cholesterol ≤ 100 mg/dl; n = 20) received 20 mg/day atorvastatin for at least 15 days pre-operatively; group II (pre-operative LDL cholesterol < 100 mg/dl; n = 20) did not receive antihyperlipidaemic agents. All patients underwent CABG with cardiopulmonary bypass. Blood samples were taken pre-operatively and 24 h post-operatively. There were no significant differences between the two groups in terms of demographic, pre-operative or operative parameters. At 24 h post-operatively, median high-sensitivity C-reactive protein and mean interleukin-6 levels were significantly lower in group I compared with group II. There were no other significant differences in postoperative parameters between the two groups, except for duration of stay in the intensive care unit, which was shorter in group I patients. In conclusion, pre-operative atorvastatin treatment in patients undergoing elective CABG decreased inflammation parameters and could be effective in preventing SIRS.

Sign in / Sign up

Export Citation Format

Share Document